Patents by Inventor Kannan Rangaramanujam
Kannan Rangaramanujam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11931418Abstract: A method for treating or preventing one or more symptoms of severe inflammation in the lung of a subject in need thereof includes administering to the subject a composition comprising dendrimers complexed, covalently conjugated, or intra-molecularly dispersed or encapsulated with one or more therapeutic or prophylactic agents, in an amount effective to treat, alleviate or prevent one or more symptoms of severe inflammation. The compositions and methods are useful for treating disorders characterized by cytokine storm, for example, for treating or preventing acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS) results in from ventilator use or infection such as with COVID-19, sepsis, and systemic bacterial infections in a subject in need thereof have been established. Preferably, the dendrimers are generation 4, 5, 6, 7, or 8 poly(amidoamine) (PAMAM) dendrimers, and the therapeutic agents are one or more anti-inflammatory and/or anti-oxidant agents such as N-acetyl cysteine.Type: GrantFiled: April 26, 2021Date of Patent: March 19, 2024Assignee: Ashvattha Therapeutics, Inc.Inventors: Jeffrey L. Cleland, Kannan Rangaramanujam, Sujatha Kannan, Jay Zaveri
-
Patent number: 11918657Abstract: Low-generation dendrimers containing a high density of surface hydroxyl groups, and methods of synthesis thereof are provided. In particular, oligo ethylene glycol (OEG)-like dendrimers with a high surface functional groups at relatively low generations (e.g. ˜120 hydroxyls in the third generation, with a size of just 1-2 nm) is described. Dendrimer formulations including one or more prophylactic, therapeutic, and/or diagnostic agents, and methods of use thereof are also described. The formulations are suitable for topical, enteral, and/or parenteral delivery for treating one or more diseases, conditions, and injuries in the eye, the brain and nervous system (CNS), particularly those associated with pathological activation of microglia and astrocytes.Type: GrantFiled: November 13, 2018Date of Patent: March 5, 2024Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Kannan Rangaramanujam, Rishi Sharma, Anjali Sharma, Sujatha Kannan, Zhi Zhang, Siva Pramodh Kambhampati
-
Publication number: 20230372499Abstract: Dendrimer compositions and methods for the treatment of cancer or autoimmune diseases are described. The compositions include dendrimers complexed or conjugated with one or more active agents for the treatment or alleviation of one or more symptoms of cancer or autoimmune diseases. The dendrimers may include one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10 dendrimers. The active agents may be immunomodulatory agents such as STING agonists, CSF1R inhibitors, PARP inhibitors, VEGFR tyrosine kinase inhibitors, MEK inhibitors, glutaminase inhibitors, TIE II antagonists, and CXCR2 inhibitors, and STING antagonists. Methods of using the dendrimer compositions to treat cancer, bone disease or inflammatory diseases are also provided.Type: ApplicationFiled: October 7, 2022Publication date: November 23, 2023Inventors: Jeffrey Cleland, Rishi Sharma, Minghao Sun, Santiago Appiani, Barbara Slusher, Rana Rais, Kannan Rangaramanujam
-
Publication number: 20230364244Abstract: In some aspects, the disclosure provides methods of treating or preventing one or more symptoms of a kidney injury, disease or disorder in a subject in need thereof. In some embodiments, the method comprises administering to the subject a dendrimer complexed, covalently conjugated, or intra-molecularly dispersed or encapsulated with one or more therapeutic or prophylactic agents, in an amount effective to treat, alleviate or prevent one or more symptoms of a kidney injury, disease or disorder. In some embodiments, the dendrimer is a. generation 4, 5, 6, 7, or 8 poly(amidoamine)(PAMAM) dendrimers, and the therapeutic agents are one or more anti-inflammatory agents and/or PPAR-? agonists.Type: ApplicationFiled: July 16, 2021Publication date: November 16, 2023Applicant: Ashvattha Therapeutics, Inc.Inventors: Jeffrey L. Cleland, Kannan Rangaramanujam, Sujatha Kannan, Rishi Sharma, Santiago Appiani La Rosa
-
Publication number: 20230338554Abstract: Compositions of dendrimers conjugated with galactose and one or more active agents to prevent, treat or diagnose a liver injury, liver disease or liver disorder in a subject in need thereof, and methods of use thereof, have been developed. Preferably, the therapeutic agents are one or more anti-inflammatory agents. The compositions are particularly suited for treating and/or ameliorating one or more symptoms of non-alcoholic steatohepatitis and severe acetaminophen poisoning. Methods of treating a human subject having or at risk of non-alcoholic steatohepatitis and severe acetaminophen poisoning are provided.Type: ApplicationFiled: September 8, 2021Publication date: October 26, 2023Inventors: Kannan Rangaramanujam, Rishi Sharma, Anjali Sharma, Joshua Porterfield, Sujatha Kannan
-
Publication number: 20230218581Abstract: Compositions of dendrimers conjugated with one or more therapeutic agents that decrease exosome secretion and methods of use thereof for treating, alleviating, and/or preventing one or more symptoms associated with one or more neurological disease or disorders, cancer, inflammatory diseases, bacterial and viral infections, and other disorders have been developed. Preferably, the therapeutic agents are one or more agents that inhibit or reduce activity and/or quantity of neutral sphingomyelinase 2 (nSMase2) such as small molecule inhibitors of nSMase2. Compositions are particularly suited for reducing A? plaque formation, reducing tau propagation, improving cognition, or combinations thereof in a subject with psychiatric and neurological disorders. Compositions are also suited for treating, alleviating, and/or preventing one or more symptoms associated with cancer, bacterial and viral infections, and inflammatory diseases.Type: ApplicationFiled: April 23, 2021Publication date: July 13, 2023Inventors: Sujatha Kannan, Rana Rais, Kannan Rangaramanujam, Anjali Sharma, Barbara Slusher, Carolyn Tallon, Ajit Thomas, Ranjeev Kumar Pandey, Jonathan Powell
-
Patent number: 11684569Abstract: Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.Type: GrantFiled: August 21, 2020Date of Patent: June 27, 2023Assignee: WAYNE STATE UNIVERSITYInventors: Kannan Rangaramanujam, Raymond Iezzi, Bharath Raja Guru, Sujatha Kannan
-
Publication number: 20230092699Abstract: The present invention provides compositions comprising PAMAM dendrimers conjugated with one or more biologically active agents, and their use systemically to target activated microglia/macrophages in retina/choroid and generally, inflammatory and/or angiogenic diseases of the eye.Type: ApplicationFiled: November 21, 2022Publication date: March 23, 2023Inventors: Kannan Rangaramanujam, Gerard Lutty, Siva Pramodh Kambhampati, Manoj Mishra, Imran Bhutto
-
Patent number: 11446238Abstract: Injectable hydrogels in the form of crosslinked nano beads or particle in the size range 5 nm to 10 ?m, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents are formed by reaction of the PAMAM dendrimer with asymmetrical end groups with linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel is formed as small crosslinked particles in the size range 25 nm to 10 ?m and is suitable for injectable delivery of hydrogel or ocular delivery for the purpose of therapeutic treatment and imaging.Type: GrantFiled: September 27, 2016Date of Patent: September 20, 2022Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Kannan Rangaramanujam, Sujatha Kannan, Roberto Romero, Raghavendra Navath, Anupa Menjoge
-
Publication number: 20220080056Abstract: A dendrimer formulation, such as a PAMAM dendrimer or a multiarm PEG polymeric formulation has been developed for oral administration to the gastrointestinal tract for treatment of inflammatory diseases associated with infection or cancer. In the preferred embodiment, the dendrimers are in the form of dendrimer nanoparticles comprising poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for treatment of one or more symptoms of necrotizing enterocolitis.Type: ApplicationFiled: September 24, 2021Publication date: March 17, 2022Inventors: David Hackam, Sujatha Kannan, Kannan Rangaramanujam, Diego F. Nino, Fan Zhang
-
Publication number: 20220071923Abstract: Compositions and methods for treating, alleviating, and/or preventing one or more symptoms associated with axonal degeneration in individuals in need thereof, such as individuals with peroxisomal disorders and leukodystrophies include one or more poly(amidoamine) dendrimers G1-G10, preferably G4-G6, complexed with therapeutic, prophylactic and/or diagnostic agent in an effective amount to treat, and/or prevent one or more symptoms associated with axonal degeneration are provided. Compositions are particularly suited for targeted delivery of therapeutics to the affected spinal neurons and may contain one or more additional targeting moieties.Type: ApplicationFiled: September 20, 2021Publication date: March 10, 2022Inventors: Sujatha Kannan, Seyed Ali Fatemi, Kannan Rangaramanujam, Fan Zhang, Bela Turk, Ozgul Gok
-
Publication number: 20210353762Abstract: A method for treating or preventing one or more symptoms of severe inflammation in the lung of a subject in need thereof includes administering to the subject a composition comprising dendrimers complexed, covalently conjugated, or intra-molecularly dispersed or encapsulated with one or more therapeutic or prophylactic agents, in an amount effective to treat, alleviate or prevent one or more symptoms of severe inflammation. The compositions and methods are useful for treating disorders characterized by cytokine storm, for example, for treating or preventing acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS) results in from ventilator use or infection such as with COVID-19, sepsis, and systemic bacterial infections in a subject in need thereof have been established. Preferably, the dendrimers are generation 4, 5, 6, 7, or 8 poly(amidoamine) (PAMAM) dendrimers, and the therapeutic agents are one or more anti-inflammatory and/or anti-oxidant agents such as N-acetyl cysteine.Type: ApplicationFiled: April 26, 2021Publication date: November 18, 2021Applicant: Ashvattha Therapeutics, Inc.Inventors: Jeffrey Cleland, Kannan Rangaramanujam, Sujatha Kannan, Jay Zaveri
-
Publication number: 20210353823Abstract: A nanoglue is formed with one or more bioadhesive polymers, one or more dendrimers, and optionally one or more therapeutic, prophylactic, or diagnostic agents. The bioadhesive polymers and dendrimers are modified with functional groups to permit crosslinking upon one or more stimuli, e.g., ultraviolet irradiation, and form hydrogel in situ at tissue sites. In the repair of corneal wounds, the nanoglue leads to improved rate of healing with less scarring and less inflammation, compared to non-treated cornea or ones treated with sutures. Therapeutic agents can be covalently conjugated to the precursor components and be delivered to specific eye compartments, providing a more efficacious treatment formulation of ocular disorders than delivering drugs in their free forms. Methods of making and using the hydrogel and hydrogel precursor compositions are also provided.Type: ApplicationFiled: February 8, 2017Publication date: November 18, 2021Inventors: Kannan Rangaramanujam, Walter Stark, Siva Pramodh Kambhampati, Uri Soiberman, Samuel Yiu, Abdul-Elah Abad Al-Towerki
-
Patent number: 11160881Abstract: Compounds, compositions, kits and methods for performing angiography related to ocular diseases, are disclosed.Type: GrantFiled: April 27, 2018Date of Patent: November 2, 2021Assignee: The Johns Hopkins UniversityInventors: Kannan Rangaramanujam, Siva Pramodh Kambhampati, Gerard Lutty, Rishi Sharma
-
Publication number: 20210252153Abstract: A composition comprising poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for the treatment or alleviation of one or more symptoms of a brain tumor have been developed. The dendrimers comprise one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10, most preferably generation 6 (G4-10-OH) dendrimers. The G6 dendrimers have demonstrated unexpectedly high uptake into the brain. The dendrimers provide a means for selective delivery through the blood brain barrier (“BBB”) of chemotherapeutic, immunotherapeutic and palliative agents. The dendrimers also have the advantage that two different classes of compounds, having one or more mechanisms of action can be bound to the dendrimers, providing simultaneous delivery. The dendrimers may be administered alone by intravenous injection, or as part of a multi-prong therapy with radiation.Type: ApplicationFiled: February 12, 2021Publication date: August 19, 2021Inventors: Antonella Mangraviti, Panagiotis Mastorakos, Manoj K. Mishra, Kannan Rangaramanujam, Betty M. Tyler, Fan Zhang
-
Publication number: 20210170040Abstract: Dendrimer compositions and methods for the treatment of cancer or autoimmune diseases are described. The compositions include dendrimers complexed or conjugated with one or more active agents for the treatment or alleviation of one or more symptoms of cancer or autoimmune diseases. The dendrimers may include one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10 dendrimers. The active agents may be immunomodulatory agents such as STING agonists, CSF1R inhibitors, PARP inhibitors, VEGFR tyrosine kinase inhibitors, MEK inhibitors, glutaminase inhibitors, TIE II antagonists, and CXCR2 inhibitors, and STING antagonists. Methods of using the dendrimer compositions to treat cancer, bone disease or inflammatory diseases are also provided.Type: ApplicationFiled: December 4, 2020Publication date: June 10, 2021Inventors: Jeffrey Cleland, Rishi Sharma, Minghao Sun, Santiago Appiani, Barbara Slusher, Rana Rais, Kannan Rangaramanujam
-
Patent number: 10918720Abstract: A composition comprising poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers covalently linked to at least one therapeutic, prophylactic or diagnostic agent for the treatment or alleviation of one or more symptoms of a brain tumor have been developed. The dendrimers comprise one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10, most preferably generation 6 (G4-10-OH) dendrimers. The G6 dendrimers have demonstrated unexpectedly high uptake into the brain. The dendrimers provide a means for selective delivery through the blood brain barrier (“BBB”) of chemotherapeutic, immunotherapeutic and palliative agents. The dendrimers also have the advantage that two different classes of compounds, having one or more mechanisms of action can be bound to the dendrimers, providing simultaneous delivery. The dendrimers may be administered alone by intravenous injection, or as part of a multi-prong therapy with radiation.Type: GrantFiled: August 13, 2015Date of Patent: February 16, 2021Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Kannan Rangaramanujam, Betty M. Tyler, Fan Zhang, Panagiotis Mastorakos, Manoj K. Mishra, Antonella Mangraviti
-
Publication number: 20200390694Abstract: Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.Type: ApplicationFiled: August 21, 2020Publication date: December 17, 2020Inventors: Kannan Rangaramanujam, Raymond Iezzi, Bharath Raja Guru, Sujatha Kannan
-
Publication number: 20200179537Abstract: Compounds, compositions, kits and methods for performing angiography related to ocular diseases, are disclosed.Type: ApplicationFiled: April 27, 2018Publication date: June 11, 2020Inventors: Kannan Rangaramanujam, Siva Pramodh Kambhampati, Gerard Lutty, Rishi Sharma
-
Publication number: 20200171200Abstract: A nanoglue is formed with one or more bioadhesive polymers, one or more dendrimers, and optionally one or more therapeutic, prophylactic, or diagnostic agents. The bioadhesive polymers and dendrimers are modified with functional groups to permit crosslinking upon one or more stimuli, e.g., ultraviolet irradiation, and form hydrogel in situ at tissue sites. In the repair of corneal wounds, the nanoglue leads to improved rate of healing with less scarring and less inflammation, compared to non-treated cornea or ones treated with sutures. Therapeutic agents can be covalently conjugated to the precursor components and be delivered to specific eye compartments, providing a more efficacious treatment formulation of ocular disorders than delivering drugs in their free forms. Methods of making and using the hydrogel and hydrogel precursor compositions are also provided.Type: ApplicationFiled: February 8, 2017Publication date: June 4, 2020Inventors: Kannan Rangaramanujam, Walter Stark, Siva Pramodh Kambhampati, Uri Soiberman, Samuel Yiu, Abdul-Elah Abad Al-Towerki